<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://jem.rupress.org">
<title>Current Print Issue</title>
<link>http://jem.rupress.org</link>
<description>Journal of Experimental Medicine RSS feed -- current issue</description>
<prism:eIssn>1540-9538</prism:eIssn>
<prism:coverDisplayDate>Oct 26 2009 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Journal of Experimental Medicine</prism:publicationName>
<prism:issn>0022-1007</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/i25?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/i26?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2304?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2304-a?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2304-b?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2305?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2305-a?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2306?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2309?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2313?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2321?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2329?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2339?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2351?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2365?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2381?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2397?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2407?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2417?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2429?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2441?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2455?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2469?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2483?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2497?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2511?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2527?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2543?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2557?rss=1" />
  <rdf:li rdf:resource="http://jem.rupress.org/cgi/content/short/206/11/2573?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://jem.rupress.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://jem.rupress.org/icons/banner/title.gif">
<title>Journal of Experimental Medicine</title>
<url>http://jem.rupress.org/icons/banner/title.gif</url>
<link>http://jem.rupress.org</link>
</image>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/i25?rss=1">
<title><![CDATA[Glyburide inhibits the Cryopyrin/Nalp3 inflammasome]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/i25?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., Lee, W. P., Hoffman, H. M., Dixit, V. M.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:01 PDT</dc:date>
<dc:identifier>info:doi/10.1084/JEM20611OIA25</dc:identifier>
<dc:title><![CDATA[Glyburide inhibits the Cryopyrin/Nalp3 inflammasome]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/i25</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>i25</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>i25</prism:startingPage>
<prism:section>From the JCB</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/i26?rss=1">
<title><![CDATA[Epidermal progenitors give rise to Merkel cells during embryonic development and adult homeostasis]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/i26?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Van Keymeulen, A., Mascre, G., Youseff, K. K., Harel, I., Michaux, C., De Geest, N., Szpalski, C., Achouri, Y., Bloch, W., Hassan, B. A., Blanpain, C.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:01 PDT</dc:date>
<dc:identifier>info:doi/10.1084/JEM20611OIA26</dc:identifier>
<dc:title><![CDATA[Epidermal progenitors give rise to Merkel cells during embryonic development and adult homeostasis]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/i26</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>i26</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>i26</prism:startingPage>
<prism:section>From the JCB</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2304?rss=1">
<title><![CDATA[Mast cells' message in a particle]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2304?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Maxmen, A.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:18:59 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20611iti1</dc:identifier>
<dc:title><![CDATA[Mast cells' message in a particle]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2304</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2304</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2304</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2304-a?rss=1">
<title><![CDATA[Revising the Th17 recipe]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2304-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Maxmen, A.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:18:59 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20611iti2</dc:identifier>
<dc:title><![CDATA[Revising the Th17 recipe]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2304-a</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2304</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2304</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2304-b?rss=1">
<title><![CDATA[How staph thwarts attack]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2304-b?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Maxmen, A.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:18:59 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20611iti3</dc:identifier>
<dc:title><![CDATA[How staph thwarts attack]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2304-b</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2305</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2304</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2305?rss=1">
<title><![CDATA[Runx: T reg cell keeper and creator]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2305?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Maxmen, A.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:18:59 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20611iti4</dc:identifier>
<dc:title><![CDATA[Runx: T reg cell keeper and creator]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2305</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2305</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2305</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2305-a?rss=1">
<title><![CDATA[Pro-fibrotic SNPs]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2305-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Maxmen, A.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:18:59 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20611iti5</dc:identifier>
<dc:title><![CDATA[Pro-fibrotic SNPs]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2305-a</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2305</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2305</prism:startingPage>
<prism:section>In This Issue</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2306?rss=1">
<title><![CDATA[Salim "Slim" Abdool Karim: Attacking AIDS in South Africa]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2306?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Maxmen, A.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:18:59 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20611pi</dc:identifier>
<dc:title><![CDATA[Salim "Slim" Abdool Karim: Attacking AIDS in South Africa]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2306</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2307</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2306</prism:startingPage>
<prism:section>PEOPLE &amp; IDEAS</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2309?rss=1">
<title><![CDATA[Masking MALT1: the paracaspase's potential for cancer therapy]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2309?rss=1</link>
<description><![CDATA[
<p>A key feature of aggressive B cell lymphomas is constitutive NF-B activation, which requires signals from the CARD11&ndash;BCL-10&ndash;MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-B inhibitor A20. New data shows that targeting MALT1 protease activity may be a promising therapeutic strategy for treating aggressive B cell lymphomas.</p>
]]></description>
<dc:creator><![CDATA[Vucic, D., Dixit, V. M.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20092160</dc:identifier>
<dc:title><![CDATA[Masking MALT1: the paracaspase's potential for cancer therapy]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2309</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2312</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2309</prism:startingPage>
<prism:section>Commentaries</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2313?rss=1">
<title><![CDATA[Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2313?rss=1</link>
<description><![CDATA[
<p>Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in humans. The aggressive activated B cell&ndash;like (ABC) subtype of DLBCL is characterized by constitutive NF-B activity and requires signals from CARD11, BCL10, and the paracaspase MALT1 for survival. CARD11, BCL10, and MALT1 are scaffold proteins that normally associate upon antigen receptor ligation. Signal-induced CARD11&ndash;BCL10&ndash;MALT1 (CBM) complexes couple upstream events to IB kinase (IKK)/NF-B activation. MALT1 also possesses a recently recognized proteolytic activity that cleaves and inactivates the negative NF-B regulator A20 and BCL10 upon antigen receptor ligation. Yet, the relevance of MALT1 proteolytic activity for malignant cell growth is unknown. Here, we demonstrate preassembled CBM complexes and constitutive proteolysis of the two known MALT1 substrates in ABC-DLBCL, but not in germinal center B cell&ndash;like (GCB) DLBCL. ABC-DLBCL cell treatment with a MALT1 protease inhibitor blocks A20 and BCL10 cleavage, reduces NF-B activity, and decreases the expression of NF-B targets genes. Finally, MALT1 paracaspase inhibition results in death and growth retardation selectively in ABC-DLBCL cells. Thus, our results indicate a growth-promoting role for MALT1 paracaspase activity in ABC-DLBCL and suggest that a pharmacological MALT1 protease inhibition could be a promising approach for lymphoma treatment.</p>
]]></description>
<dc:creator><![CDATA[Ferch, U., Kloo, B., Gewies, A., Pfander, V., Duwel, M., Peschel, C., Krappmann, D., Ruland, J.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20091167</dc:identifier>
<dc:title><![CDATA[Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2313</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2320</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2313</prism:startingPage>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2321?rss=1">
<title><![CDATA[Variants of CTGF are associated with hepatic fibrosis in Chinese, Sudanese, and Brazilians infected with Schistosomes]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2321?rss=1</link>
<description><![CDATA[
<p>Abnormal fibrosis occurs during chronic hepatic inflammations and is the principal cause of death in hepatitis C virus and schistosome infections. Hepatic fibrosis (HF) may develop either slowly or rapidly in schistosome-infected subjects. This depends, in part, on a major genetic control exerted by genes of chromosome 6q23. A gene (connective tissue growth factor [<I>CTGF</I>]) is located in that region that encodes a strongly fibrogenic molecule. We show that the single nucleotide polymorphism (SNP) rs9402373 that lies close to <I>CTGF</I> is associated with severe HF (P = 2 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;6</sup>; odds ratio [OR] = 2.01; confidence interval of OR [CI] = 1.51&ndash;2.7) in two Chinese samples, in Sudanese, and in Brazilians infected with either <I>Schistosoma japonicum</I> or <I>S. mansoni</I>. Furthermore, SNP rs12526196, also located close to <I>CTGF</I>, is independently associated with severe fibrosis (P = 6 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;4</sup>; OR = 1.94; CI = 1.32&ndash;2.82) in the Chinese and Sudanese subjects. Both variants affect nuclear factor binding and may alter gene transcription or transcript stability. The identified variants may be valuable markers for the prediction of disease progression, and identify a critical step in the development of HF that could be a target for chemotherapy.</p>
]]></description>
<dc:creator><![CDATA[Dessein, A., Chevillard, C., Arnaud, V., Hou, X., Hamdoun, A. A., Dessein, H., He, H., Abdelmaboud, S. A., Luo, X., Li, J., Varoquaux, A., Mergani, A., Abdelwahed, M., Zhou, J., Monis, A., Pitta, M. G.R., Gasmelseed, N., Cabantous, S., Zhao, Y., Prata, A., Brandt, C., Elwali, N. E., Argiro, L., Li, Y.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090383</dc:identifier>
<dc:title><![CDATA[Variants of CTGF are associated with hepatic fibrosis in Chinese, Sudanese, and Brazilians infected with Schistosomes]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2321</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2328</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2321</prism:startingPage>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2329?rss=1">
<title><![CDATA[Runx proteins regulate Foxp3 expression]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2329?rss=1</link>
<description><![CDATA[
<p>Runx proteins are essential for hematopoiesis and play an important role in T cell development by regulating key target genes, such as CD4 and CD8 as well as lymphokine genes, during the specialization of naive CD4 T cells into distinct T helper subsets. In regulatory T (T reg) cells, the signature transcription factor Foxp3 interacts with and modulates the function of several other DNA binding proteins, including Runx family members, at the protein level. We show that Runx proteins also regulate the initiation and the maintenance of <I>Foxp3</I> gene expression in CD4 T cells. Full-length Runx promoted the de novo expression of Foxp3 during inducible T reg cell differentiation, whereas the isolated dominant-negative Runt DNA binding domain antagonized de novo Foxp3 expression. Foxp3 expression in natural T reg cells remained dependent on Runx proteins and correlated with the binding of Runx/core-binding factor &beta; to regulatory elements within the <I>Foxp3</I> locus. Our data show that Runx and Foxp3 are components of a feed-forward loop in which Runx proteins contribute to the expression of Foxp3 and cooperate with Foxp3 proteins to regulate the expression of downstream target genes.</p>
]]></description>
<dc:creator><![CDATA[Bruno, L., Mazzarella, L., Hoogenkamp, M., Hertweck, A., Cobb, B. S., Sauer, S., Hadjur, S., Leleu, M., Naoe, Y., Telfer, J. C., Bonifer, C., Taniuchi, I., Fisher, A. G., Merkenschlager, M.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090226</dc:identifier>
<dc:title><![CDATA[Runx proteins regulate Foxp3 expression]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2329</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2337</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2329</prism:startingPage>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2339?rss=1">
<title><![CDATA[Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2339?rss=1</link>
<description><![CDATA[
<p>Tertiary lymphoid organs (TLOs) are organized aggregates of B and T cells formed in postembryonic life in response to chronic immune responses to infectious agents or self-antigens. Although CD11c<sup>+</sup> dendritic cells (DCs) are consistently found in regions of TLO, their contribution to TLO organization has not been studied in detail. We found that CD11c<sup>hi</sup> DCs are essential for the maintenance of inducible bronchus-associated lymphoid tissue (iBALT), a form of TLO induced in the lungs after influenza virus infection. Elimination of DCs after the virus had been cleared from the lung resulted in iBALT disintegration and reduction in germinal center (GC) reactions, which led to significantly reduced numbers of class-switched plasma cells in the lung and bone marrow and reduction in protective antiviral serum immunoglobulins. Mechanistically, DCs isolated from the lungs of mice with iBALT no longer presented viral antigens to T cells but were a source of lymphotoxin (LT) &beta; and homeostatic chemokines (CXCL-12 and -13 and CCL-19 and -21) known to contribute to TLO organization. Like depletion of DCs, blockade of LT&beta; receptor signaling after virus clearance led to disintegration of iBALT and GC reactions. Together, our data reveal a previously unappreciated function of lung DCs in iBALT homeostasis and humoral immunity to influenza virus.</p>
]]></description>
<dc:creator><![CDATA[GeurtsvanKessel, C. H., Willart, M. A.M., Bergen, I. M., van Rijt, L. S., Muskens, F., Elewaut, D., Osterhaus, A. D.M.E., Hendriks, R., Rimmelzwaan, G. F., Lambrecht, B. N.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090410</dc:identifier>
<dc:title><![CDATA[Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2339</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2349</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2339</prism:startingPage>
<prism:section>Brief Definitive Reports</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2351?rss=1">
<title><![CDATA[Id2-, ROR{gamma}t-, and LT{beta}R-independent initiation of lymphoid organogenesis in ocular immunity]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2351?rss=1</link>
<description><![CDATA[
<p>The eye is protected by the ocular immunosurveillance system. We show that tear duct&ndash;associated lymphoid tissue (TALT) is located in the mouse lacrimal sac and shares immunological characteristics with mucosa-associated lymphoid tissues (MALTs), including the presence of M cells and immunocompetent cells for antigen uptake and subsequent generation of mucosal immune responses against ocularly encountered antigens and bacteria such as <I>Pseudomonas aeruginosa</I>. Initiation of TALT genesis began postnatally; it occurred even in germ-free conditions and was independent of signaling through organogenesis regulators, including inhibitor of DNA binding/differentiation 2, retinoic acid&ndash;related orphan receptor t, lymphotoxin (LT) 1&beta;2&ndash;LT&beta;R, and lymphoid chemokines (CCL19, CCL21, and CXCL13). Thus, TALT shares immunological features with MALT but has a distinct tissue genesis mechanism and plays a key role in ocular immunity.</p>
]]></description>
<dc:creator><![CDATA[Nagatake, T., Fukuyama, S., Kim, D.-Y., Goda, K., Igarashi, O., Sato, S., Nochi, T., Sagara, H., Yokota, Y., Jetten, A. M., Kaisho, T., Akira, S., Mimuro, H., Sasakawa, C., Fukui, Y., Fujihashi, K., Akiyama, T., Inoue, J.-i., Penninger, J. M., Kunisawa, J., Kiyono, H.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20091436</dc:identifier>
<dc:title><![CDATA[Id2-, ROR{gamma}t-, and LT{beta}R-independent initiation of lymphoid organogenesis in ocular immunity]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2351</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2364</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2351</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2365?rss=1">
<title><![CDATA[Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2365?rss=1</link>
<description><![CDATA[
<p>Platelet activation at a site of vascular injury is essential for the arrest of bleeding; however, excessive platelet activation at a site of arterial damage can result in the unwarranted formation of arterial thrombi, precipitating acute myocardial infarction, or ischemic stroke. Activation of platelets beyond the purpose of hemostasis may occur when substances facilitating thrombus growth and stability accumulate. Human platelets contain matrix metalloproteinase 2 (MMP-2) and release it upon activation. Active MMP-2 amplifies the platelet aggregation response to several agonists by potentiating phosphatidylinositol 3-kinase activation. Using several in vivo thrombosis models, we show that the inactivation of the MMP-2 gene prevented thrombosis induced by weak, but not strong, stimuli in mice but produced only a moderate prolongation of the bleeding time. Moreover, using cross-transfusion experiments and <I>wild-type/MMP-2<sup>&ndash;/&ndash;</sup></I> chimeric mice, we show that it is platelet-derived MMP-2 that facilitates thrombus formation. Finally, we show that platelets activated by a mild vascular damage induce thrombus formation at a downstream arterial injury site by releasing MMP-2. Thus, platelet-derived MMP-2 plays a crucial role in thrombus formation by amplifying the response of platelets to weak activating stimuli. These findings open new possibilities for the prevention of thrombosis by the development of MMP-2 inhibitors.</p>
]]></description>
<dc:creator><![CDATA[Momi, S., Falcinelli, E., Giannini, S., Ruggeri, L., Cecchetti, L., Corazzi, T., Libert, C., Gresele, P.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090687</dc:identifier>
<dc:title><![CDATA[Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2365</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2379</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2365</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2381?rss=1">
<title><![CDATA[Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2381?rss=1</link>
<description><![CDATA[
<p>Blood coagulation starts immediately after damage to the vascular endothelium. This system is essential for minimizing blood loss from an injured blood vessel but also contributes to vascular thrombosis. Although it has long been thought that the intrinsic coagulation pathway is not important for clotting in vivo, recent data obtained with genetically altered mice indicate that contact phase proteins seem to be essential for thrombus formation. We show that recombinant <I>Ixodes ricinus</I> contact phase inhibitor (Ir-CPI), a Kunitz-type protein expressed by the salivary glands of the tick <I>Ixodes ricinus</I>, specifically interacts with activated human contact phase factors (FXIIa, FXIa, and kallikrein) and prolongs the activated partial thromboplastin time (aPTT) in vitro. The effects of Ir-CPI were also examined in vivo using both venous and arterial thrombosis models. Intravenous administration of Ir-CPI in rats and mice caused a dose-dependent reduction in venous thrombus formation and revealed a defect in the formation of arterial occlusive thrombi. Moreover, mice injected with Ir-CPI are protected against collagen- and epinephrine-induced thromboembolism. Remarkably, the effective antithrombotic dose of Ir-CPI did not promote bleeding or impair blood coagulation parameters. To conclude, our results show that a contact phase inhibitor is an effective and safe antithrombotic agent in vivo.</p>
]]></description>
<dc:creator><![CDATA[Decrem, Y., Rath, G., Blasioli, V., Cauchie, P., Robert, S., Beaufays, J., Frere, J.-M., Feron, O., Dogne, J.-M., Dessy, C., Vanhamme, L., Godfroid, E.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20091007</dc:identifier>
<dc:title><![CDATA[Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2381</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2395</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2381</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2397?rss=1">
<title><![CDATA[Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2)]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2397?rss=1</link>
<description><![CDATA[
<p>Activation of vascular smooth muscle cells (VSMCs) to migrate and proliferate is essential for the formation of intimal hyperplasia. Hence, selectively targeting activated VSMCs is a potential strategy against vaso-occlusive disorders such as in-stent restenosis, vein-graft stenosis, and transplant vasculopathy. We show that CD98 heavy chain (CD98hc) is markedly up-regulated in neointimal and cultured VSMCs, and that activated but not quiescent VSMCs require CD98hc for survival. CD98hc mediates integrin signaling and localizes amino acid transporters to the plasma membrane. SMC-specific deletion of CD98hc did not affect normal vessel morphology, indicating that CD98hc was not required for the maintenance of resident quiescent VSMCs; however, CD98hc deletion reduced intimal hyperplasia after arterial injury. Ex vivo and in vitro, loss of CD98hc suppressed proliferation and induced apoptosis in VSMCs. Furthermore, reconstitution with CD98hc mutants showed that CD98hc interaction with integrins was necessary for the survival of VSMCs. These studies establish the importance of CD98hc in VSMC proliferation and survival. Furthermore, loss of CD98hc was selectively deleterious to activated VSMCs while sparing resident quiescent VSMCs, suggesting that activated VSMCs are physiologically dependent on CD98hc, and hence, CD98hc is a potential therapeutic target in vaso-occlusive disorders.</p>
]]></description>
<dc:creator><![CDATA[Fogelstrand, P., Feral, C. C., Zargham, R., Ginsberg, M. H.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20082845</dc:identifier>
<dc:title><![CDATA[Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2)]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2397</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2406</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2397</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2407?rss=1">
<title><![CDATA[Transforming growth factor {beta} is dispensable for the molecular orchestration of Th17 cell differentiation]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2407?rss=1</link>
<description><![CDATA[
<p>Interleukin (IL)-17&ndash;producing T helper (Th17) cells play a critical role in the pathophysiology of several autoimmune disorders. The differentiation of Th17 cells requires the simultaneous presence of an unusual combination of cytokines: IL-6, a proinflammatory cytokine, and transforming growth factor (TGF) &beta;, an antiinflammatory cytokine. However, the molecular mechanisms by which TGF-&beta; exerts its effects on Th17 cell differentiation remain elusive. We report that TGF-&beta; does not directly promote Th17 cell differentiation but instead acts indirectly by blocking expression of the transcription factors signal transducer and activator of transcription (STAT) 4 and GATA-3, thus preventing Th1 and Th2 cell differentiation. In contrast, TGF-&beta; had no effect on the expression of retinoic acid receptor&ndash;related orphan nuclear receptor t, a Th17-specific transcription factor. Interestingly, in Stat-6<sup>&ndash;/&ndash;</sup>T-bet<sup>&ndash;/&ndash;</sup> mice, which are unable to generate Th1 and Th2 cells, IL-6 alone was sufficient to induce robust differentiation of Th17 cells, whereas TGF-&beta; had no effect, suggesting that TGF-&beta; is dispensable for Th17 cell development. Consequently, BALB/c Stat-6<sup>&ndash;/&ndash;</sup>T-bet<sup>&ndash;/&ndash;</sup> mice, but not wild-type BALB/c mice, were highly susceptible to the development of experimental autoimmune encephalomyelitis, which could be blocked by anti&ndash;IL-17 antibodies but not by anti&ndash;TGF-&beta; antibodies. Collectively, these data provide evidence that TGF-&beta; is not directly required for the molecular orchestration of Th17 cell differentiation.</p>
]]></description>
<dc:creator><![CDATA[Das, J., Ren, G., Zhang, L., Roberts, A. I., Zhao, X., Bothwell, A. L.M., Van Kaer, L., Shi, Y., Das, G.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20082286</dc:identifier>
<dc:title><![CDATA[Transforming growth factor {beta} is dispensable for the molecular orchestration of Th17 cell differentiation]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2407</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2416</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2407</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2417?rss=1">
<title><![CDATA[Staphylococcus aureus synthesizes adenosine to escape host immune responses]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2417?rss=1</link>
<description><![CDATA[
<p><I>Staphylococcus aureus</I> infects hospitalized or healthy individuals and represents the most frequent cause of bacteremia, treatment of which is complicated by the emergence of methicillin-resistant <I>S. aureus</I>. We examined the ability of <I>S. aureus</I> to escape phagocytic clearance in blood and identified adenosine synthase A (AdsA), a cell wall&ndash;anchored enzyme that converts adenosine monophosphate to adenosine, as a critical virulence factor. Staphylococcal synthesis of adenosine in blood, escape from phagocytic clearance, and subsequent formation of organ abscesses were all dependent on <I>adsA</I> and could be rescued by an exogenous supply of adenosine. An AdsA homologue was identified in the anthrax pathogen, and adenosine synthesis also enabled escape of <I>Bacillus anthracis</I> from phagocytic clearance. Collectively, these results suggest that staphylococci and other bacterial pathogens exploit the immunomodulatory attributes of adenosine to escape host immune responses.</p>
]]></description>
<dc:creator><![CDATA[Thammavongsa, V., Kern, J. W., Missiakas, D. M., Schneewind, O.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090097</dc:identifier>
<dc:title><![CDATA[Staphylococcus aureus synthesizes adenosine to escape host immune responses]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2417</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2427</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2417</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2429?rss=1">
<title><![CDATA[Subtilase cytotoxin cleaves newly synthesized BiP and blocks antibody secretion in B lymphocytes]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2429?rss=1</link>
<description><![CDATA[
<p>Shiga-toxigenic <I>Escherichia coli</I> (STEC) use subtilase cytotoxin (SubAB) to interfere with adaptive immunity. Its inhibition of immunoglobulin secretion is both rapid and profound. SubAB favors cleavage of the newly synthesized immunoglobulin heavy chain&ndash;binding protein (BiP) to yield a C-terminal fragment that contains BiP&rsquo;s substrate-binding domain. In the absence of its regulatory nucleotide-binding domain, the SubAB-cleaved C-terminal BiP fragment remains tightly bound to newly synthesized immunoglobulin light chains, resulting in retention of light chains in the endoplasmic reticulum (ER). Immunoglobulins are thus detained in the ER, making impossible the secretion of antibodies by SubAB-treated B cells. The inhibitory effect of SubAB is highly specific for antibody secretion, because other secretory proteins such as IL-6 are released normally from SubAB-treated B cells. Although SubAB also causes BiP cleavage in HepG2 hepatoma cells, (glyco)protein secretion continues unabated in SubAB-exposed HepG2 cells. This specific block in antibody secretion is a novel means of immune evasion for STEC. The differential cleavage of newly synthesized versus "aged" BiP by SubAB in the ER provides insight into the architecture of the ER compartments involved.</p>
]]></description>
<dc:creator><![CDATA[Hu, C.-C. A., Dougan, S. K., Winter, S. V., Paton, A. W., Paton, J. C., Ploegh, H. L.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090782</dc:identifier>
<dc:title><![CDATA[Subtilase cytotoxin cleaves newly synthesized BiP and blocks antibody secretion in B lymphocytes]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2429</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2440</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2429</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2441?rss=1">
<title><![CDATA[Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2441?rss=1</link>
<description><![CDATA[
<p>In normal T cell progenitors, phosphoinositide-dependent kinase l (PDK1)&ndash;mediated phosphorylation and activation of protein kinase B (PKB) is essential for the phosphorylation and inactivation of Foxo family transcription factors, and also controls T cell growth and proliferation. The current study has characterized the role of PDK1 in the pathology caused by deletion of the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN). PDK1 is shown to be essential for lymphomagenesis caused by deletion of PTEN in T cell progenitors. However, PTEN deletion bypasses the normal PDK1-controlled signaling pathways that determine thymocyte growth and proliferation. PDK1 does have important functions in PTEN-null thymocytes, notably to control the PKB&ndash;Foxo signaling axis and to direct the repertoire of adhesion and chemokine receptors expressed by PTEN-null T cells. The results thus provide two novel insights concerning pathological signaling caused by PTEN loss in lymphocytes. First, PTEN deletion bypasses the normal PDK1-controlled metabolic checkpoints that determine cell growth and proliferation. Second, PDK1 determines the cohort of chemokine and adhesion receptors expressed by PTEN-null cells, thereby controlling their migratory capacity.</p>
]]></description>
<dc:creator><![CDATA[Finlay, D. K., Sinclair, L. V., Feijoo, C., Waugh, C. M., Hagenbeek, T. J., Spits, H., Cantrell, D. A.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090219</dc:identifier>
<dc:title><![CDATA[Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2441</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2454</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2441</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2455?rss=1">
<title><![CDATA[Mast cell-derived particles deliver peripheral signals to remote lymph nodes]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2455?rss=1</link>
<description><![CDATA[
<p>During infection, signals from the periphery are known to reach draining lymph nodes (DLNs), but how these molecules, such as inflammatory cytokines, traverse the significant distances involved without dilution or degradation remains unclear. We show that peripheral mast cells, upon activation, release stable submicrometer heparin-based particles containing tumor necrosis factor and other proteins. These complexes enter lymphatic vessels and rapidly traffic to the DLNs. This physiological drug delivery system facilitates communication between peripheral sites of inflammation and remote secondary lymphoid tissues.</p>
]]></description>
<dc:creator><![CDATA[Kunder, C. A., St. John, A. L., Li, G., Leong, K. W., Berwin, B., Staats, H. F., Abraham, S. N.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090805</dc:identifier>
<dc:title><![CDATA[Mast cell-derived particles deliver peripheral signals to remote lymph nodes]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2455</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2467</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2455</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2469?rss=1">
<title><![CDATA[T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2469?rss=1</link>
<description><![CDATA[
<p>During a screen for ethylnitrosourea-induced mutations in mice affecting blood natural killer (NK) cells, we identified a strain, designated Duane, in which NK cells were reduced in blood and spleen but increased in lymph nodes (LNs) and bone marrow (BM). The accumulation of NK cells in LNs reflected a decreased ability to exit into lymph. This strain carries a point mutation within <I>Tbx21</I> (T-bet), which generates a defective protein. Duane NK cells have a 30-fold deficiency in sphingosine-1-phosphate receptor 5 (S1P<SUB>5</SUB>) transcript levels, and S1P<SUB>5</SUB>-deficient mice exhibit an egress defect similar to Duane. Chromatin immunoprecipitation confirms binding of T-bet to the <I>S1pr5</I> locus. S1P-deficient mice exhibit a more severe NK cell egress block, and the FTY720-sensitive S1P<SUB>1</SUB> also plays a role in NK cell egress from LNs. S1P<SUB>5</SUB> is not inhibited by CD69, a property that may facilitate trafficking of activated NK cells to effector sites. Finally, the accumulation of NK cells within BM of S1P-deficient mice was associated with reduced numbers in BM sinusoids, suggesting a role for S1P in BM egress. In summary, these findings identify S1P<SUB>5</SUB> as a T-bet&ndash;induced gene that is required for NK cell egress from LNs and BM.</p>
]]></description>
<dc:creator><![CDATA[Jenne, C. N., Enders, A., Rivera, R., Watson, S. R., Bankovich, A. J., Pereira, J. P., Xu, Y., Roots, C. M., Beilke, J. N., Banerjee, A., Reiner, S. L., Miller, S. A., Weinmann, A. S., Goodnow, C. C., Lanier, L. L., Cyster, J. G., Chun, J.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090525</dc:identifier>
<dc:title><![CDATA[T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2469</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2481</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2469</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2483?rss=1">
<title><![CDATA[Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2483?rss=1</link>
<description><![CDATA[
<p>Mesenchymal stem cells (MSCs) are defined as cells that undergo sustained in vitro growth and can give rise to multiple mesenchymal lineages. Because MSCs have only been isolated from tissue in culture, the equivalent cells have not been identified in vivo and little is known about their physiological roles or even their exact tissue location. In this study, we used phenotypic, morphological, and functional criteria to identify and prospectively isolate a subset of MSCs (PDGFR<sup>+</sup>Sca-1<sup>+</sup>CD45<sup>&ndash;</sup>TER119<sup>&ndash;</sup>) from adult mouse bone marrow. Individual MSCs generated colonies at a high frequency and could differentiate into hematopoietic niche cells, osteoblasts, and adipocytes after in vivo transplantation. Naive MSCs resided in the perivascular region in a quiescent state. This study provides the useful method needed to identify MSCs as defined in vivo entities.</p>
]]></description>
<dc:creator><![CDATA[Morikawa, S., Mabuchi, Y., Kubota, Y., Nagai, Y., Niibe, K., Hiratsu, E., Suzuki, S., Miyauchi-Hara, C., Nagoshi, N., Sunabori, T., Shimmura, S., Miyawaki, A., Nakagawa, T., Suda, T., Okano, H., Matsuzaki, Y.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20091046</dc:identifier>
<dc:title><![CDATA[Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2483</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2496</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2483</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2497?rss=1">
<title><![CDATA[CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2497?rss=1</link>
<description><![CDATA[
<p>Group 1 CD1 (CD1a, CD1b, and CD1c)&ndash;restricted T cells recognize mycobacterial lipid antigens and are found at higher frequencies in <I>Mycobacterium tuberculosis</I> (Mtb)&ndash;infected individuals. However, their role and dynamics during infection remain unknown because of the lack of a suitable small animal model. We have generated human group 1 CD1 transgenic (hCD1Tg) mice that express all three human group 1 CD1 isoforms and support the development of group 1 CD1&ndash;restricted T cells with diverse T cell receptor usage. Both mycobacterial infection and immunization with Mtb lipids elicit group 1 CD1&ndash;restricted Mtb lipid&ndash;specific T cell responses in hCD1Tg mice. In contrast to CD1d-restricted NKT cells, which rapidly respond to initial stimulation but exhibit anergy upon reexposure, group 1 CD1&ndash;restricted T cells exhibit delayed primary responses and more rapid secondary responses, similar to conventional T cells. Collectively, our data demonstrate that group 1 CD1&ndash;restricted T cells participate in adaptive immune responses upon mycobacterial infection and could serve as targets for the development of novel Mtb vaccines.</p>
]]></description>
<dc:creator><![CDATA[Felio, K., Nguyen, H., Dascher, C. C., Choi, H.-J., Li, S., Zimmer, M. I., Colmone, A., Moody, D. B., Brenner, M. B., Wang, C.-R.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:00 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090898</dc:identifier>
<dc:title><![CDATA[CD1-restricted adaptive immune responses to Mycobacteria in human group 1 CD1 transgenic mice]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2497</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2509</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2497</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2511?rss=1">
<title><![CDATA[Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2511?rss=1</link>
<description><![CDATA[
<p>Type I diabetes mellitus is caused by autoimmune destruction of pancreatic &beta; cells, and effective treatment of the disease might require rescuing &beta; cell function in a context of reinstalled immune tolerance. Sertoli cells (SCs) are found in the testes, where their main task is to provide local immunological protection and nourishment to developing germ cells. SCs engraft, self-protect, and coprotect allogeneic and xenogeneic grafts from immune destruction in different experimental settings. SCs have also been successfully implanted into the central nervous system to create a regulatory environment to the surrounding tissue which is trophic and counter-inflammatory. We report that isolated neonatal porcine SC, administered alone in highly biocompatible microcapsules, led to diabetes prevention and reversion in the respective 88 and 81% of overtly diabetic (nonobese diabetic [NOD]) mice, with no need for additional &beta; cell or insulin therapy. The effect was associated with restoration of systemic immune tolerance and detection of functional pancreatic islets that consisted of glucose-responsive and insulin-secreting cells. Curative effects by SC were strictly dependent on efficient tryptophan metabolism in the xenografts, leading to TGF-&beta;&ndash;dependent emergence of autoantigen-specific regulatory T cells and recovery of &beta; cell function in the diabetic recipients.</p>
]]></description>
<dc:creator><![CDATA[Fallarino, F., Luca, G., Calvitti, M., Mancuso, F., Nastruzzi, C., Fioretti, M. C., Grohmann, U., Becchetti, E., Burgevin, A., Kratzer, R., van Endert, P., Boon, L., Puccetti, P., Calafiore, R.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:01 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20090134</dc:identifier>
<dc:title><![CDATA[Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2511</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2526</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2511</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2527?rss=1">
<title><![CDATA[A hypomorphic allele of ZAP-70 reveals a distinct thymic threshold for autoimmune disease versus autoimmune reactivity]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2527?rss=1</link>
<description><![CDATA[
<p>ZAP-70 is critical for T cell receptor (TCR) signaling. Tyrosine to phenylalanine mutations of Y315 and Y319 in ZAP-70 suggest these residues function to recruit downstream effector molecules, but mutagenesis and crystallization studies reveal that these residues also play an important role in autoinhibition ZAP-70. To address the importance of the scaffolding function, we generated a <I>zap70</I> mutant mouse (YYAA mouse) with Y315 and Y319 both mutated to alanines. These YYAA mice reveal that the scaffolding function is important for normal development and function. Moreover, the YYAA mice have many similarities to a previously identified ZAP-70 mutant mouse, SKG, which harbors a distinct hypomorphic mutation. Both YYAA and SKG mice have impaired T cell development and hyporesponsiveness to TCR stimulation, markedly reduced numbers of thymic T regulatory cells and defective positive and negative selection. YYAA mice, like SKG mice, develop rheumatoid factor antibodies, but fail to develop autoimmune arthritis. Signaling differences that result from ZAP-70 mutations appear to skew the TCR repertoire in ways that differentially influence propensity to autoimmunity versus autoimmune disease susceptibility. By uncoupling the relative contribution from T regulatory cells and TCR repertoire during thymic selection, our data help to identify events that may be important, but alone are insufficient, for the development of autoimmune disease.</p>
]]></description>
<dc:creator><![CDATA[Hsu, L.-Y., Tan, Y. X., Xiao, Z., Malissen, M., Weiss, A.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:01 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20082902</dc:identifier>
<dc:title><![CDATA[A hypomorphic allele of ZAP-70 reveals a distinct thymic threshold for autoimmune disease versus autoimmune reactivity]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2527</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2541</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2527</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2543?rss=1">
<title><![CDATA[Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2543?rss=1</link>
<description><![CDATA[
<p>Of the potent lipid inflammatory mediators comprising the cysteinyl leukotrienes (LTs; LTC<SUB>4</SUB>, LTD<SUB>4</SUB>, and LTE<SUB>4</SUB>), only LTE<SUB>4</SUB> is stable and abundant in vivo. Although LTE<SUB>4</SUB> shows negligible activity at the type 1 and 2 receptors for cys-LTs (CysLT<SUB>1</SUB>R and CysLT<SUB>2</SUB>R), it is a powerful inducer of mucosal eosinophilia and airway hyperresponsiveness in humans with asthma. We show that the adenosine diphosphate (ADP)&ndash;reactive purinergic (P2Y<SUB>12</SUB>) receptor is required for LTE<SUB>4</SUB>-mediated pulmonary inflammation. P2Y<SUB>12</SUB> receptor expression permits LTE<SUB>4</SUB> -induced activation of extracellular signal-regulated kinase in Chinese hamster ovary cells and permits chemokine and prostaglandin D<SUB>2</SUB> production by LAD2 cells, a human mast cell line. P2Y<SUB>12</SUB> receptor expression by LAD2 cells is required for competition between radiolabeled ADP and unlabeled LTE<SUB>4</SUB> but not for direct binding of LTE<SUB>4</SUB>, suggesting that P2Y<SUB>12</SUB> complexes with another receptor to recognize LTE<SUB>4</SUB>. Administration of LTE<SUB>4</SUB> to the airways of sensitized mice potentiates eosinophilia, goblet cell metaplasia, and expression of interleukin-13 in response to low-dose aerosolized allergen. These responses persist in mice lacking both CysLT<SUB>1</SUB>R and CysLT<SUB>2</SUB>R but not in mice lacking P2Y<SUB>12</SUB> receptors. The effects of LTE<SUB>4</SUB> on P2Y<SUB>12</SUB> in the airway were abrogated by platelet depletion. Thus, the P2Y<SUB>12</SUB> receptor is required for proinflammatory actions of the stable abundant mediator LTE<SUB>4</SUB> and is a novel potential therapeutic target for asthma.</p>
]]></description>
<dc:creator><![CDATA[Paruchuri, S., Tashimo, H., Feng, C., Maekawa, A., Xing, W., Jiang, Y., Kanaoka, Y., Conley, P., Boyce, J. A.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:01 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20091240</dc:identifier>
<dc:title><![CDATA[Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2543</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2555</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2543</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2557?rss=1">
<title><![CDATA[KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2557?rss=1</link>
<description><![CDATA[
<p>Human killer cell immunoglobulin-like receptors (KIRs) are distinguished by expansion of activating KIR2DS, whose ligands and functions remain poorly understood. The oldest, most prevalent KIR2DS is KIR2DS4, which is represented by a variable balance between "full-length" and "deleted" forms. We find that full-length 2DS4 is a human histocompatibility leukocyte antigen (HLA) class I receptor that binds specifically to subsets of C1<sup>+</sup> and C2<sup>+</sup> HLA-C and to HLA-A*11, whereas deleted 2DS4 is nonfunctional. Activation of 2DS4<sup>+</sup> NKL cells was achieved with A*1102 as ligand, which differs from A*1101 by unique substitution of lysine 19 for glutamate, but not with A*1101 or HLA-C. Distinguishing KIR2DS4 from other KIR2DS is the proline&ndash;valine motif at positions 71&ndash;72, which is shared with KIR3DL2 and was introduced by gene conversion before separation of the human and chimpanzee lineages. Site-directed swap mutagenesis shows that these two residues are largely responsible for the unique HLA class I specificity of KIR2DS4. Determination of the crystallographic structure of KIR2DS4 shows two major differences from KIR2DL: displacement of contact loop L2 and altered bonding potential because of the substitutions at positions 71 and 72. Correlation between the worldwide distributions of functional KIR2DS4 and HLA-A*11 points to the physiological importance of their mutual interaction.</p>
]]></description>
<dc:creator><![CDATA[Graef, T., Moesta, A. K., Norman, P. J., Abi-Rached, L., Vago, L., Older Aguilar, A. M., Gleimer, M., Hammond, J. A., Guethlein, L. A., Bushnell, D. A., Robinson, P. J., Parham, P.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:01 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.20091010</dc:identifier>
<dc:title><![CDATA[KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2557</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2572</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2557</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://jem.rupress.org/cgi/content/short/206/11/2573?rss=1">
<title><![CDATA[Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6]]></title>
<link>http://jem.rupress.org/cgi/content/short/206/11/2573?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Machado, F. S., Esper, L., Dias, A., Madan, R., Gu, Y., Hildeman, D., Serhan, C. N., Karp, C. L., Aliberti, J.]]></dc:creator>
<dc:date>Mon, 26 Oct 2009 09:19:01 PDT</dc:date>
<dc:identifier>info:doi/10.1084/jem.2007241692209r</dc:identifier>
<dc:title><![CDATA[Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6]]></dc:title>
<dc:publisher>The Rockefeller University Press</dc:publisher>
<prism:object>hw_mjid:jem;206/11/2573</prism:object>
<prism:number>11</prism:number>
<prism:volume>206</prism:volume>
<prism:endingPage>2573</prism:endingPage>
<prism:publicationDate>2009-10-26</prism:publicationDate>
<prism:startingPage>2573</prism:startingPage>
<prism:section>RETRACTION</prism:section>
</item>

</rdf:RDF>